Skip to Main Content

Author Details

Pamela J Provan
Westmead Institute for Medical Research, Westmead Hospital, The University of Sydney
2006
17
9
PMIDPaper TitleJournal TitlePublished Year
36805919Older age should not be a barrier to testing for somatic variants in homologous recombination DNA repair-related genes in patients with high-grade serous ovarian carcinoma.Transl Oncol2023
36805919Older age should not be a barrier to testing for somatic variants in homologous recombination DNA repair-related genes in patients with high-grade serous ovarian carcinoma.Transl Oncol2023
36456881The genomic and immune landscape of long-term survivors of high-grade serous ovarian cancer.Nat Genet2022
36456881The genomic and immune landscape of long-term survivors of high-grade serous ovarian cancer.Nat Genet2022
34454680Cell-free DNA is abundant in ascites and represents a liquid biopsy of ovarian cancer.Gynecol Oncol2021
34454680Cell-free DNA is abundant in ascites and represents a liquid biopsy of ovarian cancer.Gynecol Oncol2021
31082762Tamoxifen-induced severe hot flashes and endoxifen levels: is dose reduction a safe and effective strategy?Breast2019
31082762Tamoxifen-induced severe hot flashes and endoxifen levels: is dose reduction a safe and effective strategy?Breast2019
29214365Profiling differential microRNA expression between in situ, infiltrative and lympho-vascular space invasive breast cancer: a pilot study.Clin Exp Metastasis2018
29214365Profiling differential microRNA expression between in situ, infiltrative and lympho-vascular space invasive breast cancer: a pilot study.Clin Exp Metastasis2018
27372543Embedding continuous quality improvement processes in multidisciplinary teams in cancer care: exploring the boundaries between quality and implementation science.Aust Health Rev2017
27372543Embedding continuous quality improvement processes in multidisciplinary teams in cancer care: exploring the boundaries between quality and implementation science.Aust Health Rev2017
26847054Dose Escalation of Tamoxifen in Patients with Low Endoxifen Level: Evidence for Therapeutic Drug Monitoring-The TADE Study.Clin Cancer Res2016
26847054Dose Escalation of Tamoxifen in Patients with Low Endoxifen Level: Evidence for Therapeutic Drug Monitoring-The TADE Study.Clin Cancer Res2016
27357641The Sydney West Knowledge Portal: Evaluating the Growth of a Knowledge Portal to Support Translational Research.J Med Internet Res2016
27357641The Sydney West Knowledge Portal: Evaluating the Growth of a Knowledge Portal to Support Translational Research.J Med Internet Res2016
24403187The prognostic value of Ki67 in systemically untreated patients with node-negative breast cancer.J Clin Pathol2014
24403187The prognostic value of Ki67 in systemically untreated patients with node-negative breast cancer.J Clin Pathol2014
24247619Prohibitin expression is associated with high grade breast cancer but is not a driver of amplification at 17q21.33.Pathology2013
24247619Prohibitin expression is associated with high grade breast cancer but is not a driver of amplification at 17q21.33.Pathology2013
23099207Characteristics of HER2-positive breast cancer diagnosed following the introduction of universal HER2 testing.Breast2012
23099207Characteristics of HER2-positive breast cancer diagnosed following the introduction of universal HER2 testing.Breast2012
20025477A class discovery and class prediction approach to histopathological classification of mammographic screen detected columnar cell lesions of the breast.Pathology2010
20815029Familial concordance of breast cancer pathology as an indicator of genotype in multiple-case families.Genes Chromosomes Cancer2010
20473278Diagnostic evaluation of papillary lesions of the breast on core biopsy.Mod Pathol2010
20025477A class discovery and class prediction approach to histopathological classification of mammographic screen detected columnar cell lesions of the breast.Pathology2010
20815029Familial concordance of breast cancer pathology as an indicator of genotype in multiple-case families.Genes Chromosomes Cancer2010
20473278Diagnostic evaluation of papillary lesions of the breast on core biopsy.Mod Pathol2010
18446624Histopathological features of 'BRCAX' familial breast cancers in the kConFab resource.Pathology2008
18927304Poor-prognosis estrogen receptor-positive breast cancer identified by histopathologic subclassification.Clin Cancer Res2008
18446624Histopathological features of 'BRCAX' familial breast cancers in the kConFab resource.Pathology2008
18927304Poor-prognosis estrogen receptor-positive breast cancer identified by histopathologic subclassification.Clin Cancer Res2008
17064299Histopathological features of breast cancer in carriers of ATM gene variants.Histopathology2006
17064299Histopathological features of breast cancer in carriers of ATM gene variants.Histopathology2006
  • 1 - 34 of 34

Recommended Authors

University of Bern
Career Start Year 2009
Number of shared co-authors 5
Instituto Do Cancer Do Estado de Sao Paulo
Career Start Year 2009
Number of shared co-authors 2
Stanford University School of Medicine
Career Start Year 2008
Number of shared co-authors 0
Pathology Queensland The Royal Brisbane and Women's Hospital Brisbane Qld Australia.
Career Start Year 2007
Number of shared co-authors 4
Memorial Sloan Kettering Cancer Center
Career Start Year 2007
Number of shared co-authors 1
University of British Columbia
Career Start Year 2007
Number of shared co-authors 18
University of California San Francisco
Career Start Year 2005
Number of shared co-authors 3
University of Turin, Candiolo Cancer Institute, FPO-IRCCS
Career Start Year 2005
Number of shared co-authors 0
Erasmus MC Cancer Institute
Career Start Year 2004
Number of shared co-authors 6
National Cancer Institute
Career Start Year 2004
Number of shared co-authors 3
Beth Israel Deaconess Medical Center, Harvard Medical School
Career Start Year 2004
Number of shared co-authors 3
UQ Centre for Clinical Research, The University of Queensland
Career Start Year 2003
Number of shared co-authors 7
Olivia Newton-John Cancer Research Institute
Career Start Year 2002
Number of shared co-authors 3
IEO European Institute of Oncology IRCCS
Career Start Year 2002
Number of shared co-authors 0
Memorial Sloan Kettering Cancer Center
Career Start Year 2002
Number of shared co-authors 9
Familial Cancer Centre Peter MacCallum Cancer Centre Parkville Victoria 0 Australia.
Career Start Year 1998
Number of shared co-authors 19
Lund University and Skane University Hospital
Career Start Year 1997
Number of shared co-authors 3
Memorial Sloan-Kettering Cancer Center
Career Start Year 1996
Number of shared co-authors 7
Radboud University Medical Center
Career Start Year 1994
Number of shared co-authors 0
University Health Network
Career Start Year 1994
Number of shared co-authors 0
Cancer Research UK Cambridge Institute, University of Cambridge
Career Start Year 1992
Number of shared co-authors 11
University of Edinburgh
Career Start Year 1992
Number of shared co-authors 2
Fred Hutchinson Cancer Research Center
Career Start Year 1991
Number of shared co-authors 1
Erasmus Medical Center (MC) Cancer Institute
Career Start Year 1989
Number of shared co-authors 8
University Medical Center Utrecht
Career Start Year 1989
Number of shared co-authors 0
Queen Elizabeth University Hospital
Career Start Year 1986
Number of shared co-authors 0
University of California San Francisco
Career Start Year 1984
Number of shared co-authors 9
University of Queensland
Career Start Year 1983
Number of shared co-authors 15
Pathologisches Institut, Universitatsklinikum Heidelberg
Career Start Year 1981
Number of shared co-authors 25
Yale University School of Medicine
Career Start Year 1980
Number of shared co-authors 0

Collaborators

Westmead Institute for Medical Research, The University of Sydney
Co-authored papers 13
Westmead Hospital
Co-authored papers 9
Prince of Wales Hospital
Co-authored papers 5
Westmead Institute for Medical Research, University of Sydney
Co-authored papers 4
Westmead Hospital
Co-authored papers 3
Westmead Clinical School, University of Sydney
Co-authored papers 3
School of Public Health, Imperial College London
Co-authored papers 2
Co-authored papers 2
The Canberra Hospital
Co-authored papers 2
Westmead Institute for Medical Research
Co-authored papers 2
University of Sydney
Co-authored papers 2
Crown Princess Mary Cancer Centre, Westmead Hospital
Co-authored papers 2
Sydney West Area Health Service
Co-authored papers 2
Peter MacCallum Cancer Centre
Co-authored papers 2
Westmead Hospital
Co-authored papers 2
School of Clinical Medicine, University of NSW Sydney, Lowy Cancer Research Centre
Co-authored papers 2
The University of Melbourne
Co-authored papers 1
Mayo Clinic College of Medicine
Co-authored papers 1
Center for Cancer Research, National Cancer Institute, National Institutes of Health
Co-authored papers 1
Memorial Sloan-Kettering Cancer Center
Co-authored papers 1
Mayo Clinic
Co-authored papers 1
The Westmead Institute for Medical Research, University of Sydney
Co-authored papers 1
Peter MacCallum Cancer Centre
Co-authored papers 1
Johns Hopkins School of Medicine, National Cancer Institute, Princeton University, University of Colorado Anschutz Medical Campus, University of Pittsburgh, University of Washington
Co-authored papers 1
Center for Individualized Medicine, Mayo Clinic
Co-authored papers 1
Co-authored papers 1
University of Michigan School of Public Health ann arbor
Co-authored papers 1
Peter MacCallum Cancer Centre
Co-authored papers 1
CRUK Cambridge Institute, University of Cambridge
Co-authored papers 1
Division of Clinical Trials and Biostatistics, Mayo Clinic
Co-authored papers 1